20082024

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2018

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Alamgeer, M., Neil Watkins, D., Banakh, I., Kumar, B., Gough, D. J., Markman, B. & Ganju, V., 1 Apr 2018, In : Investigational New Drugs. 36, 2, p. 288-298 11 p.

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., 1 Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)
2014

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., Miles, D. & LoRusso, P. M., 2014, In : Clinical Cancer Research. 20, 9, p. 2445 - 2456 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
66 Citations (Scopus)
2013

PI3K pathway inhibitors: better not left alone

Markman, B., Tao, J. J. & Scaltriti, M., 2013, In : Current Pharmaceutical Design. 19, 5, p. 895 - 906 12 p.

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)
2012

Application of monoclonal antibodies as cancer therapy in solid tumors

Dienstmann, R., Markman, B. & Tabernero, J., 2012, In : Current Clinical Pharmacology. 7, 2, p. 137 - 145 9 p.

Research output: Contribution to journalArticleOther

30 Citations (Scopus)
2011

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors

Paz-Ares, L., Gomez-Roca, C., Delord, J-P., Cervantes, A., Markman, B., Corral, J., Soria, J-C., Berge, Y., Roda, D., Russell-Yarde, F., Hollingsworth, S., Baselga, J., Umana, P., Manenti, L. & Tabernero, J., 2011, In : Journal of Clinical Oncology. 29, 28, p. 3783 - 3790 8 p.

Research output: Contribution to journalArticleResearchpeer-review

60 Citations (Scopus)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P., Ibrahim, Y., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Rusillo, M., Parra, J., Singh, S., Arribas, J., Rosen, N. & Baselga, J., 2011, In : Oncogene. 30, 22, p. 2547 - 2557 11 p.

Research output: Contribution to journalArticleResearchpeer-review

343 Citations (Scopus)

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2

Dienstmann, R., Rodon, J., Markman, B. & Tabernero, J., 2011, In : Recent Patents on Anti-Cancer Drug Discovery. 6, 2, p. 210 - 236 27 p.

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)
2010

Biomarkers in colorectal cancer

Markman, B., Rodriguez-Freixinos, V. & Tabernero, J., 2010, In : Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.. 12, 4, p. 261 - 270 10 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy

Serrano, C., Markman, B. & Tabernero, J., 2010, In : Cancer Journal. 16, 3, p. 226 - 234 9 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Monoclonal antibodies in solid tumours

Markman, B. & Tabernero, J., 2010, In : Current Clinical Pharmacology. 5, 3, p. 160 - 165 6 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Status of PI3K inhibition and biomarker development in cancer therapeutics

Markman, B., Atzori, F., Perez-Garcia, J., Tabernero, J. & Baselga, J., 2010, In : Annals of Oncology. 21, 4, p. 683 - 691 9 p.

Research output: Contribution to journalArticleResearchpeer-review

125 Citations (Scopus)

Targeting the PI3K/Akt/mTOR pathway - Beyond rapalogs

Markman, B., Dienstmann, R. & Tabernero, J., 2010, In : Oncotarget. 1, 7, p. 530 - 543 14 p.

Research output: Contribution to journalArticleResearchpeer-review

235 Citations (Scopus)
2009

New approaches and targets in advanced colorectal cancer

Macarulla, T., Capdevila, J., Perez-Garcia, J., Ramos, F. J., Elez, M. E., Markman, B., Ruiz-Echarri, M. & Tabernero, J., 2009, In : European Journal of Cancer. 45, Supp 1, p. 79 - 88 10 p.

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

New trends in epidermal growth factor receptor-directed monoclonal antibodies

Markman, B., Capdevila, J., Elez, M. & Tabernero, J., 2009, In : Immunotherapy. 1, 6, p. 965 - 982 18 p.

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Therapeutic armamentarium in metastatic colorectal cancer

Macarulla, T., Markman, B. & Tabernero, J., 2009, In : European Gastroenterology & Hepatology Review. 5, p. 64 - 68 5 p.

Research output: Contribution to journalArticleOther

2008

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. L., Arribas, J. & Baselga, J., 2008, In : Cancer Research. 68, 19, p. 8022 - 8030 9 p.

Research output: Contribution to journalArticleResearchpeer-review

603 Citations (Scopus)